SSY Group Limited (LJUIF)
SSY Group Limited operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Hong Kong, HK. The stock last traded at $0.40, up 0.00% on the session, giving a market capitalisation of $1.19B. On trailing twelve-month figures it carries a trailing P/E of 15.88, a net margin of 11.6%. Its beta of 0.53 implies it has historically moved less than the broad market.
SSY Group Limited functions as an investment holding company, primarily focused on the research, development, manufacturing, and distribution of a wide array of pharmaceutical goods. Its products reach hospitals and distributors across the People's Republic of China and international markets. The company's extensive product portfolio encompasses various intravenous (IV) infusion solutions, including formulations in non-PVC soft bags, upright soft bags, robust PP plastic bottles, and traditional glass bottles. It also provides ampoule and small volume injections, oral preparations, and both traditional Chinese and biological medicines. Furthermore, SSY Group supplies bulk pharmaceutical ingredients and essential medical materials. Beyond pharmaceuticals, the company engages in pharmaceutical technology research, development, and consulting services, alongside offering logistics support for its medical products. Uniquely, it also holds interests in the food, beverages, and catering sectors. Many of its offerings are marketed under the 'Shimen' brand. Established in 2004, the firm was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. before adopting the SSY Group Limited name in May 2015. It maintains its corporate headquarters in Wanchai, Hong Kong, and operates as a subsidiary of China Pharmaceutical Co., Ltd.
SSY Group Limited is most often compared with the following Healthcare names: